ELTP - Elite Pharmaceuticals, Inc.
| Previous Close | 0.09200 |
| Open | 0.09200 |
| Bid | 0.00000 x 0 |
| Ask | 0.00000 x 0 |
| Day's Range | 0.09000 - 0.09495 |
| 52 Week Range | 0.06000 - 0.25000 |
| Volume | 267,089 |
| Avg. Volume | 625,033 |
| Market Cap | 72.93M |
| Beta | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.01100 |
| Earnings Date | Feb 9, 2018 - Feb 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- ACCESSWIRE•2 months ago
New Research: Key Drivers of Growth for U.S. Stem Cell Inc. and Elite Pharmaceuticals - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of U.S. Stem Cell Inc. ( OTCQB: USRM ) and Elite Pharmaceuticals Inc. ...
- ACCESSWIRE•2 months ago
Elite Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 12, 2018 / Elite Pharmaceuticals, Inc. (OTCQB: ELTP ) will be discussing their earnings results in their Q3 Earnings Call to be held on February 12, 2018 at 11:30 AM ...
- GlobeNewswire•2 months ago
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2018 Ended December 31, 2017
NORTHVALE, N.J., Feb. 09, 2018-- Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the third quarter of ...
- GlobeNewswire•2 months ago
Elite Pharmaceuticals and SunGen Pharma File ANDA
NORTHVALE, N.J., Feb. 08, 2018-- Elite Pharmaceuticals, Inc. a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it has filed an Abbreviated ...
- GlobeNewswire•3 months ago
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss Third Quarter Financial Results on February 12, 2018
NORTHVALE, N.J., Feb. 07, 2018-- Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that the third ...
- GlobeNewswire•3 months ago
Elite Pharmaceuticals Reports Positive Topline Results from SequestOx™ Pilot Study
NORTHVALE, N.J., Jan. 30, 2018-- Elite Pharmaceuticals, Inc. today reported positive topline results from a pilot study conducted for SequestOx™, Elite’ s immediate release Oxycodone Hydrochloride product ...
Capital Cube•10 months agoElite Pharmaceuticals, Inc. :ELTP-US: Earnings Analysis: Q4, 2017 By the Numbers : June 16, 2017
Categories: Yahoo FinanceGet free summary analysis Elite Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Elite Pharmaceuticals, Inc. – Mylan N.V., Acura Pharmaceuticals, Inc., Cambrex Corporation, Aceto Corporation, Nektar Therapeutics, Pfizer Inc. and Albany Molecular Research, Inc. (MYL-US, ACUR-US, CBM-US, ACET-US, NKTR-US, PFE-US ... Read more (Read more...)